UroToday.com· @urotoday · X·· 2 天前评分70
正文 · 机器翻译
围手术期使用 Pembro 或 EV + Pembro 治疗不适合接受顺铂治疗的 #MIBC：KEYNOTE-905 的事后分析。由 Anders Ullén 医学博士报告。#ESMO26 文字报道由 @chavarriagaj @PSH_Urology > https://bit.ly/4ieyBr7 #BladderCancer #Immunotherapy
292 浏览 · 4 赞 · 4 转发 · 0 回复
会议摘要
4733O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.orgNCT03924895NCT03924895按 - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) 对上
- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
https://esmocongress.esmo.org来源：UroToday.com · x.com